Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index
نویسندگان
چکیده
منابع مشابه
Evaluating multiple treatment courses in clinical trials.
In oncology, a patient's treatment often involves multiple courses of chemotherapy. The most common medical practice in choosing treatments for successive courses is to repeat a treatment that is successful in a given course and otherwise switch to a different treatment. Patient outcome thus consists of a sequence of dependent response variables and corresponding treatments. Despite the widespr...
متن کاملCancer Therapy: Clinical Toxicity Attribution in Phase I Trials: Evaluating theEffectofDoseon theFrequencyofRelatedand Unrelated Toxicities
Purpose: Phase I studies rely on investigators to accurately attribute adverse events as related or unrelated to study drug. This information is ultimately used to help establish a safe dose. Attribution in the phase I setting has not been widely studied andassessing the accuracy of attribution is complicatedby the lack of a gold standard. We examined dose–toxicity relationships as a function o...
متن کاملAssociation between treatment toxicity and outcomes in oncology clinical trials.
BACKGROUND Whether or not toxicity predicts clinical outcomes has long been a question regarding cancer treatments. While prior studies have focused on specific cancers, therapies, and toxicities, no comprehensive evidence exists on whether treatment toxicity predicts favorable outcomes. METHODS We abstracted treatment toxicity and clinical outcome data from a sample of phase III oncology ran...
متن کاملClinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster
Background: Acyclovir, a specific and selective inhibitor of replication of herpesviridae family, has well documented efficacy for speedy rash healing and decreasing pain of herpes zoster. Limited oral bioavailability of acyclovir requires frequent dosing. Valacyclovir is rapidly and almost completely converted to acyclovir in vivo and gives three to fivefold increase in acyclovir bioavailabili...
متن کاملBiomarkers of Toxicity Panel in Clinical Trials
T he notion of “biomarker” is not new. FDA defines a biomarker as the measurable endpoint that can be used as an indicator of a particular disease or some other physiological state of an organism. There are numerous publications in the literature addressing the importance of biomarkers in clinical trials, and especially in drug development. In a clinical laboratory, testing for biomarkers can v...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2020
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/djaa028